210 related articles for article (PubMed ID: 12160363)
1. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes.
Molldrem JJ; Leifer E; Bahceci E; Saunthararajah Y; Rivera M; Dunbar C; Liu J; Nakamura R; Young NS; Barrett AJ
Ann Intern Med; 2002 Aug; 137(3):156-63. PubMed ID: 12160363
[TBL] [Abstract][Full Text] [Related]
2. Summaries for patients. Promising therapy for bone marrow failure from myelodysplastic syndromes.
Ann Intern Med; 2002 Aug; 137(3):I-27. PubMed ID: 12160383
[No Abstract] [Full Text] [Related]
3. Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
Kelaidi C; Braun T; Arana R; Marceau-Renaut A; Lazarian G; Soret J; Cereja S; Letestu R; Eclache V; Lusina D; Baran-Marszak F; Ades L; Preudhomme C; Martin A; Fenaux P; Gardin C
Leuk Res; 2018 Aug; 71():67-74. PubMed ID: 30025278
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.
Passweg JR; Giagounidis AA; Simcock M; Aul C; Dobbelstein C; Stadler M; Ossenkoppele G; Hofmann WK; Schilling K; Tichelli A; Ganser A
J Clin Oncol; 2011 Jan; 29(3):303-9. PubMed ID: 21149672
[TBL] [Abstract][Full Text] [Related]
5. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia.
Killick SB; Mufti G; Cavenagh JD; Mijovic A; Peacock JL; Gordon-Smith EC; Bowen DT; Marsh JC
Br J Haematol; 2003 Feb; 120(4):679-84. PubMed ID: 12588356
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
8. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes.
Broliden PA; Dahl IM; Hast R; Johansson B; Juvonen E; Kjeldsen L; Porwit-MacDonald A; Sjoo M; Tangen JM; Uggla B; Oberg G; Hellstrom-Lindberg E
Haematologica; 2006 May; 91(5):667-70. PubMed ID: 16670072
[TBL] [Abstract][Full Text] [Related]
9. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.
Breccia M; Latagliata R; Cannella L; Carmosino I; Santopietro M; Loglisci G; Federico V; Alimena G
Leuk Lymphoma; 2010 May; 51(5):783-8. PubMed ID: 20302387
[TBL] [Abstract][Full Text] [Related]
10. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia.
Yoshimi A; Baumann I; Führer M; Bergsträsser E; Göbel U; Sykora KW; Klingebiel T; Gross-Wieltsch U; van den Heuvel-Eibrink MM; Fischer A; Nöllke P; Niemeyer C
Haematologica; 2007 Mar; 92(3):397-400. PubMed ID: 17339190
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.
Champlin R; Ho W; Gale RP
N Engl J Med; 1983 Jan; 308(3):113-8. PubMed ID: 6336819
[TBL] [Abstract][Full Text] [Related]
13. Antithymocyte globulin for patients with myelodysplastic syndrome.
Molldrem JJ; Caples M; Mavroudis D; Plante M; Young NS; Barrett AJ
Br J Haematol; 1997 Dec; 99(3):699-705. PubMed ID: 9401087
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin.
de-Medeiros CR; Ribeiro RC; Bittencourt MA; Zanis-Neto J; Pasquini R
Braz J Med Biol Res; 2000 May; 33(5):553-8. PubMed ID: 10775887
[TBL] [Abstract][Full Text] [Related]
15. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.
Xiao L; Qi Z; Qiusheng C; Li X; Luxi S; Lingyun W
Am J Hematol; 2012 Jan; 87(1):26-31. PubMed ID: 22038646
[TBL] [Abstract][Full Text] [Related]
16. [Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome].
Takanashi M; Kadono Y; Tabata Y; Hibi S
Rinsho Ketsueki; 1999 Oct; 40(10):1093-9. PubMed ID: 10565227
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of lenalidomide in myelodysplastic syndromes.
List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy for myelodysplastic syndromes: refining the indications.
Barrett AJ; Sloand EM
Curr Hematol Malig Rep; 2008 Jan; 3(1):23-8. PubMed ID: 20425443
[TBL] [Abstract][Full Text] [Related]
19. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
20. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
